Pharmaceuticals
-
How first dose has saved lives
The first dose of vaccine has cut rates of COVID-19 disease among elderly people by about two thirds, according to a major analysis published yesterday. Read more
-
COVID vaccination gives huge boost to post-infection immunity
Vaccination is acting as a booster dose for people already enjoying some protection against COVID-19 after exposure to the disease, British scientists reported last night. Read more
-
Muscle pain not affected by statins
Muscle pain is not exacerbated by the use of statins, according to the results of a UK trial, published today. Read more
-
How UK vaccination is saving many from the virus
The first dose of the first COVID-19 vaccine has cut risk of dying from the virus by three quarters among its first elderly recipients, according to “early data”, released yesterday. Read more
-
Therapy might block multiple sclerosis autoimmune process
A new study has shown how harmful immune cells travel to the brain in people with multiple sclerosis and lead to disease progression. Read more
-
COVID phase one trials get UK bulk test approach
The UK is to adapt an innovative clinical trial procedure in a bid to fast-track untested new drugs for COVID-19 treatment, it has been announced. Read more
-
Acupressure backed for severe pregnancy sickness
Women with severe pregnancy sickness can be offered acupressure and antiemetics, according to new official guidance. Read more
-
Oxford vaccine prevents hospital admission – WHO
The Oxford University COVID-19 vaccine has gained key backing from international experts after a series of controversies. Read more
-
Opioids and macrolides ‘safe’ in pregnancy
No links have been found between taking prescription opioids or macrolide antibiotics during pregnancy and an increased risk of major birth defects, two new studies report today. Read more
-
Asthma linked to antibiotic exposure in utero
Children born to women who took antibiotics in mid or late pregnancy may have a raised risk of asthma, researchers report today. Read more
